NIH Director Francis Collins and David Liu of the Broad Institute have teamed up to conduct a study utilizing CRISPR, the genome-editing system, to see what they could do in terms of altering the aging process in mice.
At the moment, eight clinical trials are currently being carried out to determine if the link between melatonin and the novel coronavirus is legitimate.
A critical vote is set to take place today amongst those on a U.S. Food and Drug Administration advisory panel in regard to the COVID-19 vaccine from Moderna.
Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie.
Relay Therapeutics announced today that it has entered a global license and collaboration agreement with Genentech for the commercialization and development of RLY-1971.
A COVID-19 vaccine being developed by CSL Ltd., and the University of Queensland was scrapped this week after numerous vaccine recipients reported receiving false positives on certain HIV tests.
Cambridge-based Faze Medicines, the biotechnology company that develops therapeutics based on biomolecular condensates, announced today that it has raised $81 million in a Series A round of financing.
UK regulators stated today that they have received two reports of potential allergic reactions linked to the COVID-19 vaccine from Pfizer and BioNTech.
The funds will be used to support the development of the company’s REMaster technology platform. In addition, Remix will now be able to advance its pipeline of RNA processing targeted therapeutics as well.
Constellation Pharmaceuticals announced on Sunday that it has received preliminary data from its Phase II MANIFEST and Phase III MANIFEST-2 clinical trials involving CPI-0610 for myelofibrosis.
BioCryst Pharmaceuticals, Inc. announced on Thursday that the U.S. Food and Drug Administration (FDA) has approved ORLADEYO (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and young patients 12 years and older.
Merck KGaA and Artios Pharma Limited announced today that they have entered a strategic collaboration agreement to discover and develop multiple precision oncology drugs over the course of the next three years.
Auris Medical rose by as much as 480% yesterday after it announced lab test results, which appeared to show that its nasal spray could potentially protect users against COVID-19.
